Author	Session Title
POD 1: AMD	
	Global Real-World Clinical and Anatomical Outcomes With Faricimab in Treatment-Naive Patients With nAMD or DME: The VOYAGER Study
Ferhina Ali, MD, MPH	Early Real-World Use of Aflibercept 8-mg in Treatment-Naive Patients With Neovascular Age-Related Macular Degeneration
	A Pooled Analysis of the PULSAR and PHOTON Trials Through 96 Weeks: Minimal Impact of Aflibercept 8 mg and 2 mg on Intraocular Pressure Changes
	Impact of the Optimization of Surgical Procedure on the Incidence of Endophthalmitis and Associated Outcomes of Patients in PDS Trials
	SPECTRUM: Early Global Real-World Results With Aflibercept 8 mg in Patients With Previously Treated Neovascular Age-Related Macular Degeneration
Justis Ehlers, MD, FASRS	Relationship of Future Vision Loss to Baseline Central Ellipsoid Zone Integrity Features in the GATHER Clinical Trials
	A Pooled Analysis of the CANDELA, PHOTON, and PULSAR Trials: Comparably Low Intraocular Inflammation-Related Events With Aflibercept 8 mg and 2 mg
	Greater and More Durable Fluid Resolution With Aflibercept 8 mg vs Aflibercept 2 mg in the PULSAR Trial: A 96-Week Post Hoc Analysis
	Real-World Survey on Physician Treatment Choice and Dosing Schedules for Anti-VEGF Therapies in the Treatment of Neovascular Age- Related Macular Degeneration
•	SPECTRUM: Early Global Real-World Results With Aflibercept 8 mg in Patients With Treatment-Naive Neovascular Age-Related Macular Degeneration
-	Faricimab Real-World Data Support Clinical Trial Data in Patients With Treatment-Naive nAMD: Results From TENAYA/LUCERNE and FARETINA/FARWIDE
Kyung Tae Kang, MD, PhD	2-Year Follow-Up Study of Patients With Neovascular Age-Related Macular Degeneration Undergoing Anti-VEGF Treatment During the COVID-19 Pandemic
	Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: First-Time 3.5-Year Results of the TRUCKEE Study
Anton Kolomeyer, MD, PhD	Current Utilization and Trends in Antiangiogenic and Anticomplement Therapeutics
• • • • • • • • • • • • • • • • • • •	Real-World Safety Profile of Avacincaptad Pegol in the Management of Geographic Atrophy
Timothy Lai, MD	Pigment Epithelial Detachment Outcomes With Aflibercept 8 mg vs Aflibercept 2 mg in the PULSAR trial: A 96-Week Post hoc Analysis
Robert Lowe, MD	Comparison of the Efficacy of Aflibercept and Bevacizumab in the Treatment of Neovascular Age-Related Macular Degeneration
	VERDANT Phase 2 Trial: Evaluating BI 771716 vs Active Comparator in Geographic Atrophy Secondary to AM
Deepika Malik, MD	Fluctuations in Pigment Epithelial Detachment Thickness in the Archway Phase 3 Trial of the PDS
	Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration in Australia: 6-Month Interim Analysis of the FURGGHORN Study
Praveen Patel, MBBChir MA FRCOphth MD(Res)	Real-World Outcomes of Faricimab in nAMD From the United Kingdom: 18-Month Results From the FARWIDE-nAMD Study
Osama Sabbagh, MD	Emergence of Cystoid Spaces on Optical Coherence Tomography Following Intravitreal Complement Inhibitor Therapy
	Early Insights From Real-World Use of Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Switching From Other Anti-VEGF Agents
	Mitigating Conjunctival Erosions in Patients Treated With the PDS: Surgical Management and Clinical Outcomes
Ivan Suner, MD, MBA	A Pilot Study Evaluating a Novel, Compounded, Lower-Concentration Combination Povidone-Iodine and Proparacaine Eye Drop For Intravitreal Injections

Colin Tan, MBBS, MMed (Ophth), FRCSEd (Ophth) Correlation of Optical Coherence Tomography Angiography and Indocyanine Green Angiography in Polypoidal Choroidal Vasculopathy
Yoshihiro Yonekawa, MD, FASRS	Machine Learning-Based 3D Volumetric Analysis of Pigment Epithelial Detachment Reduction With Faricimab vs Aflibercept in TENAYA/LUCERNE
POD 2: Diabetic Retinopathy	
Ashkan Abbey, MD, FASRS, FAAO	Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched-Dosing Phase of PHOTON in Patients With DME Who Later Met Shortening Criteria
Ahmed Algethami, MD	Level of Glycemic Control (HbA1c) Among Patients Undergoing Surgical Treatment for Advanced Diabetic Retinopathy at Tertiary Eye Center
Durga Borkar, MD	Real-World Visual Outcomes After Vision-Threatening Complications (VTC) and Treatment in Patients With Diabetic Retinopathy (DR)
Matthew Cunningham, MD, FASRS	Outcomes of Patients With Diabetes and Postoperative Vitreous Hemorrhage Treated With Intravitreal Bevacizumab
Manjot Gill, MD, MS, FRCS (C), FASRS	Baseline Characteristics and Outcomes of Patients With Shortened, Maintained, or Extended Aflibercept 8-mg Dosing Intervals Through 96 Weeks in PHOTON
Gabriela Grimaldi, MD	SPECTRUM: Early Global Real-World Results With Aflibercept 8 mg in Patients With Treatment-Naive Diabetic Macular Edema
Chirag Jhaveri, MD, FASRS	Pharmacokinetics (PK) of BI 764524 After Intravitreal Therapy (IVT) in Diabetic Macular Ischemia (DMI) Patients: Insights From the HORNBILL Study
Michael Klufas, MD	Predictors of Extended Treatment Intervals in Patients With DME Treated With Faricimab in the Phase 3 YOSEMITE/RHINE Trials
Theodore Leng, MD, MS, FASRS	Network Meta-analyses of Number of Injections With Aflibercept 8 mg vs Faricimab in nAMD and DME
Nitish Mehta, MD	Early Insights on the Real-World Use of Aflibercept 8 mg Among Treatment-Naive Eyes With Diabetic Macular Edema
Quan Nguyen, MD, MSc, FARVO, FASRS	CRIMSON, a Phase IIb Randomized Controlled Trial of BI 764524 in Patients With NPRD: Rationale, Study Design, and Protocol
Ian Pearce, MB ChB BSc FRCOPHTH	Real-World Outcomes of Faricimab in DME From the United Kingdom: 1-Year Results From the FARWIDE-DME Study
Cynthia Qian, MD	SPECTRUM: Early Global Real-World Results With Aflibercept 8 mg in Patients With Previously Treated Diabetic Macular Edema
Bradley Smith, MD, FASRS	Short-Term Efficacy of Aflibercept HD Compared to Faricimab-svoa for Diabetic Macular Edema
Manju Subramanian, MD	Prophylactic Bevacizumab for Recurrent Vitreous Hemorrhage Following Vitrectomy in Proliferative Diabetic Retinopathy
Karen Wai, MD	Mortality Rates Following Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
POD 3: Practice Management - Risk Managemer	
Joseph Abraham, MD	Quality Improvement in Vitreoretinal Surgery: Single-Center Report on Utility of Routine Intravenous Fluids in Pars Plana Vitrectomy
Hasenin Al-khersan, MD	Supply Chain Volatility of Repackaged Intravitreal Bevacizumab: A Survey of the American Society of Retina Specialists
David Chin Yee, MD, FASRS	AI Teammates in Clinical Trials: Reducing Site Burden and Enhancing Research Efficiency
Suzie Gasparian, MD	Publication Rate of Abstracts Presented at the American Society of Retina Specialists (ASRS) Annual Meetings
William Johnson, M.D.	Weather Interruption of Nonelective Treatment and Evaluation in Retina (WINTER) Study
Sarah Kamal, MD	Association of the Social Deprivation Index With the Severity and Treatment of Diabetic Retinopathy
Prashant Tailor, MD	Comparative Analysis of LLM-Based Automated Extraction vs Manual Curation of Free-Text Notes in an ROP Dataset
Jay Wang, MD	Large Language Models in 2025: Performance in the Evaluation of Multimodal Retinal Images
POD 4: Surgical Techniques and Maneuvers & Su	urgical Complications
Radwan Ajlan, MBBCh, FRCS(C)	Endoscopic Vitreoretinal Surgery's Impact on Retina Practice at a Tertiary Care Center
Michael Altaweel, MD	A Reliable Method for Sutureless Closure of Leaking Sclerotomies With Diathermy
Parnian Arjmand, MD, MSc, FRCSC, DABO	Postoperative Optical Coherence Tomography (OCT) Characteristics of Macular Holes Repaired With the Inverted Internal Limiting Membrane Flap Technique
Michelle Carle, MD. MMEd	Rapid MIRAgel Sceral Buckle Removal

Katarzyna Chwiejczak, MD, FEBO	Short-Term Tamponade With Perfluorocarbon Liquid: Safe and Effective Management for Retinal Detachment With Subretinal Bleeding in Complex Scenarios
Andrea Cusumano, MD	Intracameral Cefuroxime Ocular Toxic Syndrome (ICOTS) in Eyes With Disrupted Intraocular Barrier: Structural and Functional Insights
Muhamad Festok, MD	Surgical Outcomes of Viscostretch Technique for Advanced Macular Hole Repair
MATTEO FORLINI, MD	Use of Heavy Silicone Oil as a Midterm Tamponade in Retinal Detachment Surgery: Efficacy and Safety
Mrinali Gupta, MD, FASRS	Efficiency of Tetra-Spot vs Single-Spot Endolaser During 25-Gauge Vitrectomy Surgery
Matias Iglicki, MD	Technological Influence on Retina Fellows' Learning Curves: A Prospective Study of Digital vs Analog Microscopes: The BRAVE Study
Tatsushi Kaga, MD, PhD	Usefulness of Ocular Endoscope in Vitreous Surgery in 3 Cases of Globe Rupture Due to Blunt Trauma
	Retinal Redetachment Post Vitrectomy: A New Indication for Endoillumination-Assisted Scleral Buckling (EASB)
Bryon McKay, MD, PhD, FRCSC, DRCPSC - Retina	Refractive and Clinical Outcomes of Secondary Intraocular Lens Surgery Between Intrascleral Haptic Fixation Technique vs Scleral Sutured MX60E Lenses
Geovanni Rios, MD	Visual Outcomes in Patients Operated With Bimanual Pars Plana Vitrectomy for Management of Advanced Tractional Retinal Detachment Due to Diabetic Retinopathy
Patrick Staropoli, MD	Visual and Anatomic Outcomes of Multiple Techniques for Primary Scleral Buckle Repair of Rhegmatogenous Retinal Detachments
Mudit Tyagi, MS, FASRS	Fibrin Glue-Assisted Hemostasis in Persistent Intraoperative Optic Disc Bleeding in Vitreoretinal Surgeries
Priya Vakharia, MD, FASRS	The Impact of Suturing Superior Sclerotomies in Immediate Postoperative Complications in Scleral-Sutured Lenses
Jessica Xiong, BMed/MD, MMed	Outcomes and Complications of Yamane Scleral-Fixated Secondary Intraocular Lens
POD 5: Retinal Detachment & Retinal Vascular Di	sease
Kunihiko Akiyama, MD, PhD	Progression of Epiretinal Membrane Following Retinal Detachment Repair With Pneumatic Retinopexy vs Vitrectomy
William Anderson, MD	Faricimab for RVO: Evaluating Clinical Outcomes in Aflibercept-Treated Patients
J. Fernando Arevalo, MD, PhD, FACS, FASRS	Clinical Impact of Continuous Drug Delivery via the PDS in Retinal Diseases
Narciso Atienza, MD, MBA, FASRS, FPCS, FPAO.	Postoperative Vitreous Cavity Hemorrhage on Diabetic Vitrectomy Patients: A 10-Year Review
Cindy Cai, MD	Similar Risk of Kidney Failure Among Patients With Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An OHDSI Network Study
Carl Danzig, MD	Association of Early Macular Leakage Resolution With Extended Dosing Intervals in Patients With RVO: A BALATON/COMINO Post Hoc Analysis
Francesco Faraldi, MD	Postoperative Multimodal Evaluation of Primary Rhegmatogenous Retinal Detachment (RRD) Surgery With Triamcinolone-Assisted Vitreous Cortex Remnants (VCR) Removal
Mallika Goyal, MD	Strategic Use of Oral Acetazolamide to Increase Treatment Interval During Anti-VEGF Therapy for Recurrent Macular Edema Secondary to Retinal Vein Occlusion
Juan Carlos Gutierrez, MD, FASRS	Retinal Displacement After Pneumatic Retinopexy in a Costa Rican Cohort
Muhammad Hassan, MD	Management and Outcomes of Bilateral Simultaneous Rhegmatogenous Retinal Detachments (BSRRD)
Makoto Inoue, MD, FASRS	Surgical Outcome of Vitrectomy for Idiopathic Vasoproliferative Retinal Tumor
Aditya Kelkar, MS, FRCS, FASRS, FRCOphth	Redetachment Rates in Traumatic vs Atraumatic Pediatric Retinal Detachment: A Retrospective Study
Jeffrey Mah, MD	Association Between Outer Retinal Corrugations and Retinal Break Status in Rhegmatogenous Retinal Detachment
Emmanouil Mavrikakis, MD, PhD, FASRS	Small-Gauge Vitrectomy for Rhegmatogenous Retinal Detachment: 3-Year Results
Andrew Moshfeghi, MD, MBA, FASRS	The Burden of Treatment With Antivascular Endothelial Growth Factor Injection on Patients and Healthcare Professionals: A Qualitative Study
Raja Narayanan, MD, MBA, FASRS	Perfluorocarbon Liquid and Silicone Oil Sandwich Technique in Complex Rhegmatogenous Retinal Detachments

Murat Oncel, MD, FASRS	Vitrectomy With Inferior Retinectomy vs Heavy Silicone Oil in the Management of Inferior Retinal Detachment With Proliferative Vitreoretinopathy
Chetan Rao, MS	Optimizing Treatment Timing in Retinal Vein Occlusion: Functional and Anatomical Outcomes of Early vs Delayed Anti-VEGF Therapy
Pradeepa Yoganathan, MSc, MD, FRCS(C)	Outcomes of Densiron Xtra Heavy Silicone Oil Endotamponade
POD 6: Ocular Oncology & Pediatric Retina	
Sulaiman Al Sulaiman, MD	The Saudi Arabian National Retinopathy of Prematurity Telemedicine Program: 6-Year Outcomes
Ronnie Manaysay, MD	Early Postnatal Weight Gain, Hemoglobin Levels, and Oxygen Saturation as Predictors of Progression of Retinopathy of Prematurity: A
	Retrospective Cohort Study
Tara McCannel, MD, PhD	Growing Circumscribed Choroidal Hemangioma With Bullous Exudation: Vision-Saving Role of Vitrectomy
Mohammad Riazi, MD	Factors Influencing the Progression of Impending Retinopathy of Prematurity (ROP) to Advanced Disease
Frances Wu, MD	Update on T-Cell Intraocular Lymphoma
Amirfarbod Yazdanyar, MD , PhD	MDM2 Variants Impact Tumor Progression, Metastasis, and Survival in Uveal Melanoma Patients
POD 7: Macular Holes & Macular Pucker	
Adel Al Akeely, MD MBA	Management of Macular Hole-Related Retinal Detachment After ILM Peeling in Proliferative Sickle Retinopathy
Carmen Baumann, MD, PhD, FEBO	Predictive Factors for Visual Acuity and Metamorphopsia After Epiretinal Membrane Surgery
Andrei DRIMBEA, MD	2024 Macular Hole Study of the French Retina and Vitreous Surgical Society
Rita Ehrlich, MD	Prognostic Factors for Development of Gliosis After Internal Limited Membrane Flap for Idiopathic Macular Holes
Colin McCannel, MD	Preoperative Visual Acuity is Excellent Predictor of Postoperative Visual Acuity for Epiretinal Membrane Surgery in 278 Eyes
Pedro Monsalve, MD	Traditional ILM Peeling vs ILM Flaps: Impact on Success of Reoperations for Macular Holes That Don't Close With the First Surgery
Zhaotian Zhang, MD	Semi-staining Technique to Create a Nonstained Internal Limiting Membrane Flap to Cover Large Idiopathic Macular Holes
POD 8: Imaging & Instrumentation	
Jorge Fortun, MD	A Novel Method of Measuring Contrast Sensitivity Function in Patients Undergoing Vitrectomy for Symptomatic Floaters
Sunir Garg, MD, FACS, FASRS	Effect of Topical Bromfenac 0.09% on Pain Following Antivascular Endothelial Growth Factor Intravitreal Injections (IVI)
Hussain Khaqan, MD, FRCS, FCPS,	A Novel Classification of Optic Disc Pit and Serous Macular Detachment Based on Surgical Management
Firas Rahhal, MD	Time Efficiency of Endolaser Panretinal Photocoagulation Procedure With Multispot Laser Probe: A Prospective, Comparative, Observational Study
Richard Roe, MD, MHS	Console Setup and Teardown Time Efficiency for Vitreoretinal Surgery With Next-Generation System: A Prospective, Comparative, Observational Study
Tsai-Chu Yeh, MD, MTM	A Simplified Classification for Age-Related Macular Degeneration Based on Optical Coherence Tomography
POD 9: Inflammatory and Infectious Disease 8	
Mathew MacCumber, MD, PhD	Safety Profile of Oral Gildeuretinol Acetate: Safety Results Across TEASE-1, TEASE-3, and SAGA Clinical Studies
Alejandro Marin, MD	Clinical Impact of Suprachoroidal Triamcinolone Acetonide (SCS-TA) in the Management of Complex Noninfectious Cystoid Macular Edema (CME)
Ramiro Maldonado, MD	Safety and Efficacy of OCU410ST—a Novel Modifier Gene Therapy—for Treatment of Stargardt Disease: Phase 1/2 Study Update
Sawsan Nowilaty, MD, FASRS	The Phenotypic Spectrum of Autosomal Recessive Bestrophinopathy and Retinal Features in Carriers
Eduardo Uchiyama, MD, FACS	Real-World Treatment Patterns and Ocular Morbidity in Patients With Uveitic Macular Edema Secondary to Noninfectious Uveitis in the United States
Νο CME	
Jorge Arroyo, MD, MPH	Accelerating Surgical Innovation With Office-Based Surgery and STYCH.TV: One Stream at a Time

ASRS 2025 Papers-on-Demand

Michael Singer, MD	NEW DAY: Results of a randomized, active-controlled clinical trial of Fluocinolone Acetonide 0.19 mg Intravitreal Implant for Diabetic
	Macular Edema